A new real-world study in Greece finds that for high-risk patients, COVID-19 antivirals are highly effective in reducing the risk of both hospitalization and death. The study is published in The Journal of Infectious Diseases.
Patients who were older than 75, and reported good drug adherence benefitted the most from the drugs molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid)
... Other countries are taking similar action as the more transmissible — yet, apparently, less virulent — omicron variant spreads through the continent.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/REV4SO7HRVJVBA6SMVGTLXD4KE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/M5NT4EWIONOTLGJVNI7FXCLVDQ.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/PL5C564OSZP7RA45K7JBH2FYYQ.jpg)
